OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Braun on the Current Kidney Cancer Treatment Paradigm

August 16th 2024

David A. Braun, MD, PhD, discusses the variety of therapies available for the treatment of patients with kidney cancer.

Dr Kim on Current Unmet Needs in the Management of Resectable CRC

August 16th 2024

Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.

Dr Miller on the Use of NK Cell Therapy in Hematologic Malignancies

August 16th 2024

Jeffrey S. Miller, MD, discusses research with natural killer cell therapy in patients with hematologic malignancies and other cancers.

Dr Stiles on the FDA Approval of Perioperative Durvalumab Plus Chemo in NSCLC

August 15th 2024

Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.

Dr Christenson on the Safety of Copanlisib Plus Nivolumab in Pretreated MSS mCRC

August 15th 2024

Eric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.

Dr Hursting on Weight Loss Drugs and the Potential to Reduce Obesity-Related Breast Cancer

August 15th 2024

Dr Randall on the Role of EZH2 in Doxorubicin Resistance in Soft Tissue Sarcoma

August 15th 2024

R. Lor Randall, MD, FACS, discusses the role of EZH2 in doxorubicin resistance in soft tissue sarcoma.

Dr Kalinsky on Unmet Needs and Findings from RxPONDER in HR+/HER2– Breast Cancer

August 15th 2024

Kevin Kalinsky, MD, MS, discusses AMH levels and responses in premenopausal HR+/HER2–, node-positive breast cancer.

Dr Adam on Efforts to Reduce Recurrence Risk in CRC Liver Metastases

August 15th 2024

Rene Adam, MD, PhD, discusses future research aimed at reducing the risk of recurrence in patients with unresectable colorectal liver metastases

Dr Trudel on the Significance of the DREAMM-7 and DREAMM-8 Trials in R/R Multiple Myeloma

August 15th 2024

Suzanne Trudel, MSc, MD, discusses the implications of results from the DREAMM-7 and DREAMM-8 trials in relapsed/refractory multiple myeloma.

Dr Cremolini on the Implications of the TRANSMET Trial in Colorectal Liver Metastases

August 15th 2024

Chiara Cremolini, MD, PhD, discusses the implications of the TRANSMET trial in patients with unresectable colorectal liver metastases.

Dr Oswalt on the Effects of Palliative Care Timing on End-of-Life Care in mNSCLC

August 15th 2024

Cameron James Oswalt MD, discusses a study evaluating the timing of palliative care referral and its effect on end-of-life care outcomes in mNSCLC.

Dr Hantel on Environmental and Health Impacts of Decentralizing Cancer Care

August 15th 2024

Andrew Hantel, MD, discusses the environmental and health impacts of decentralizing cancer care in response to high emissions generated by health care.

Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC

August 15th 2024

Soki Kashima, MD, PhD, discusses a study investigating T-cell phenotypes associated with response or resistance to checkpoint inhibitors in RCC.

Dr Raez on the FDA Approval of Repotrectinib in NTRK+ Solid Tumors

August 14th 2024

Luis E. Raez, MD, FACP, FCCP, discusses the significance of the FDA approval of repotrectinib in solid tumors harboring an NTRK gene fusion.

Dr Mouabbi on Challenges Diagnosing and Managing Invasive Lobular Carcinoma

August 14th 2024

Jason A. Mouabbi, MD, discusses challenges associated with diagnosing and managing invasive lobular carcinoma

Dr Long on Unmet Needs in BRAF-Mutant Melanoma

August 14th 2024

Georgina Long, MBBS, PhD, FRACP, discusses unmet needs for BRAF-mutant melanoma, highlighting key insights from the phase 3 NADINA trial.

Dr Feldman on the Prevention and Management of Breast Cancer–Related Lymphedema

August 14th 2024

Sheldon Feldman, MD, discusses prevention and management strategies for breast cancer–related lymphedema.

Dr Serzan on the Rationale for Evaluating Botensilimab Plus Balstilimab in Advanced RCC

August 14th 2024

Michael Serzan, MD, discusses the rationale for evaluating botensilimab/balstilimab for patients with advanced renal cell carcinoma.

Dr Ravi on Neoadjuvant ARPIs Prior to Radical Prostatectomy in Prostate Cancer

August 14th 2024

Praful K. Ravi, MB, BChir, MRCP, discusses the use of neoadjuvant androgen receptor pathway inhibitors prior to radical prostatectomy in high-risk, localized prostate cancer.